Brokerage firm Geojit has identified bullish technical patterns in Avalon Technologies and Healthcare Global Enterprises following their recent quarterly results. Both stocks have moved past key resistance levels, drawing attention to their current market trends and operational performance.
Brokerage firm Geojit has recently pointed to favorable technical developments in Avalon Technologies and Healthcare Global Enterprises (HCG). The brokerage's latest analysis observes that both companies have witnessed positive momentum, with technical indicators suggesting a shift in trend. This comes alongside recent quarterly results and corporate updates that have caught the attention of market observers.
Avalon Technologies: Technical Breakout And Financial Growth
Avalon Technologies has shown a technical breakout from a double-bottom formation, a pattern often associated with a reversal from a previous downward trend. As of August 11, 2026, the stock has been trading near ₹1,965. The recent market interest follows a strong showing in the company's Q1 FY27 financial results, where the firm reported a consolidated net profit of ₹34.9 crore, compared to ₹14.2 crore in the same period last year. This growth highlights the company's expanding presence in the electronics manufacturing services (EMS) sector.
While technical indicators like volume growth and moving averages point to positive momentum, investors typically weigh these against the inherent risks in the EMS space. Companies in this sector are often subject to supply chain complexities and potential timing uncertainties in large-scale program ramp-ups. The brokerage report mentions a potential price target of ₹2,200, but shareholders often monitor these technical levels alongside actual execution and raw material availability.
Healthcare Global Enterprises: Focus On Expansion
Healthcare Global Enterprises (HCG) has also been highlighted for breaking out of a long-term consolidation range. The stock, which was trading around ₹716 as of August 10, 2026, has seen an uptick in volume. This technical move coincides with the company’s ongoing focus on its oncology and specialty healthcare segments. In early August 2026, HCG announced an investment of ₹16 crore into HCG Rajkot Hospitals LLP, signalling the firm's intent to continue its capital-intensive hospital expansion strategy.
However, the company’s recent Q1 performance was described as mixed, with revenue challenges balancing out strong operational metrics. Because HCG operates in a competitive specialty healthcare market, investors often track how effectively the company manages the debt associated with these new hospital projects. Additionally, with higher valuation multiples, the stock’s future performance may depend on consistent earnings growth and the successful commissioning of its new healthcare facilities. The brokerage report noted a near-term potential target of ₹760 for the stock, though market participants generally assess these levels against the backdrop of sector-wide competition and the risks associated with high valuations.